Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Cancer Companies

ESMO: Ayala In Shadow Of SpringWorks In Rare Cancer Race

Israeli Biotech’s Stock Down Despite Desmoid Tumor Success

  • News

Executive Summary

The companies’ respective gamma-secretase inhibitors provided positive data for desmoid tumors at the ESMO congress but SpringWork’s nirogacestat impressed the most.

You may also be interested in...



SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease

Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.

Advaxis To Seek New Life In Merger With Ayala

The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Cancer Companies
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC147047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By